High-Tech Cord Blood Banking One of several things it has going for it.
•AmStem will make inroads to link up Histostem’s vast repository of genetically desirable Cord Blood Units (CBUs) with other international networks that provide HLA-typed cord blood samples directly to physicians for the off-label treatment of their patients. A new European Patent was recently awarded to support this.
•These high-quality CBUs, monitored and quality-controlled by a state-of-the-art cryopreservation system, will also be made available to researchers at major hospitals and universities around the world. Two recent hospitals have recently opened the gateway to the vast Chinese medical market by awarding a contract to Histostem.
•Histostem was recently granted a new US Patent for their proprietary method on deriving the maximum number of viable stem cells from a frozen cord blood specimen. This gives AmStem a strategic advantage in controlling one of the most efficient and non-controversial supply chain, storage, and delivery systems for stem cells in the world.
Market Data 
Markets 
AI
